Latest News Release

Oncolytics Biotech Inc. Closes $16.48 Million Private Placement

Oncolytics Biotech Inc. Announces $16.48 Million Private Placement

Oncolytics Biotech Inc. to Webcast Clinical Trial Update for REOLYSIN®

Oncolytics Biotech Inc. to Present at the Rodman & Renshaw TechVest 7th Annual Healthcare Conference

Oncolytics Biotech Inc. Announces 2005 Third Quarter Results

Oncolytics Biotech Inc. Announces Issuance of Third Canadian Patent-Therapeutic Use of the Reovirus to Treat Cancers

Oncolytics Biotech Inc. Ends Patient Treatment in Canadian Phase I Recurrent Malignant Glioma Clinical Trial

Oncolytics Biotech Inc. to Present at BIO InvestorForum in San Francisco


Year

Oncolytics Biotech® Announces Poster Presentation at the 2018 Gastrointestinal Cancers Symposium Sponsored by ASCO in Patients with Relapsed Metastatic Adenocarcinoma of the Pancreas Read More

Oncolytics Biotech® Receives Favorable Final Advice Letter from the European Medicines Agency for REOLYSIN® in Metastatic Breast Cancer Read More

View all news articles

Exploring REOLYSIN®’s Objective Response Rate in Females with Colorectal Cancer Read More

Exploring REOLYSIN<sup>®</sup>’s Objective Response Rate in Females with Colorectal Cancer thumbail
View all blog posts

LATEST TWEETS

Follow us on Twitter